Category

0
17
NICE recommends Stelara (ustekinumab) for the treatment of active psoriatic arthritis
Janssen has announced that the National Institute for Health and Clinical Excellence (NICE), has recommended Stelara® (ustekinumab) in its Final Appraisal Determination (FAD)1 as...
medicalnewstoday.com
almost 6 years ago

0
1
Boehringer Ingelheim's investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study
For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*.
medicalnewstoday.com
almost 6 years ago

0
4
Results from Phase III study evaluating oral otezla or injectable etanercept versus placebo in patients with moderate to severe plaque psoriasis
Celgene Corporation has announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4...
medicalnewstoday.com
almost 6 years ago

0
5
New antibody therapy dramatically improves psoriasis symptoms in clinical trial
Only a single treatment produced what researchers describe as 'rapid, substantial, and durable clinical...
medicalnewstoday.com
almost 6 years ago

0
6
Cosentyx (secukinumab) is the first IL-17A inhibitor to be available for moderate to severe plaque psoriasis in the UK
Novartis Pharmaceuticals UK Limited (Novartis) has announced that Cosentyx (secukinumab) is available for use in the UK for the treatment of moderate to severe plaque psoriasis in adults who...
medicalnewstoday.com
almost 6 years ago

0
11
Marshaling the body's own weapons against psoriasis
Immunotherapy with natural signaling substance relieves skin conditionA three-character code brings relief to patients with psoriasis and sheds light on complex...
medicalnewstoday.com
almost 6 years ago

0
11
First independent U.S. psoriasis registry to track drug safety and effectiveness
People with psoriasis and their health care providers will have the opportunity to participate in research that aims to improve treatments and disease outcomes when the first independent U.S.
medicalnewstoday.com
almost 6 years ago

0
5
Researchers find gene that confirms existence of psoriatic arthritis
PsA is a common form of inflammatory form of arthritis causing pain and stiffness in joints and tendons that can lead to joint damage.
medicalnewstoday.com
almost 6 years ago

0
7
Provectus Biopharmaceuticals begins recruitment for phase 2 mechanism of action clinical trial of PH-10 for psoriasis
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company ('Provectus'), has announced that it has opened recruitment for its phase 2 mechanism...
medicalnewstoday.com
almost 6 years ago

0
3
Proteins identified that are likely to trigger psoriasis
Case Western Reserve scientists have taken a huge leap toward identifying root causes of psoriasis, an inflammatory skin condition affecting 125 million people around the world.
medicalnewstoday.com
almost 6 years ago

0
7
FDA approves new psoriasis drug Cosentyx
The U.S. Food and Drug Administration has approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.
medicalnewstoday.com
almost 6 years ago

0
6
Psoriasis: Otezla (apremilast), receives European marketing authorisation in two therapeutic indications
Celgene UK has announced that the European Commission has licensed Otezla, the Company's oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic...
medicalnewstoday.com
almost 6 years ago

0
10
Review article estimates annual U.S. cost of psoriasis in 2013
The annual U.S. cost of psoriasis, a chronic inflammatory skin condition, was estimated to be between $112 billion and $135 billion in 2013, according to a review article published online by...
medicalnewstoday.com
almost 6 years ago

0
4
US regulatory submission of the first aerosol foam for psoriasis
LEO Pharma announced it has submitted a New Drug Application to the US Food and Drug Administration (FDA) for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the...
medicalnewstoday.com
almost 6 years ago

0
5
Psoriatic Arthritis and the Heart: Is There a Risk?
Study finds many commonalities, but no evidence of excess mortality.
medpagetoday.com
almost 6 years ago

0
13
Oral fumaric acid esters for the treatment of psoriasis | Cochrane
Psoriasis is a long-term inflammatory skin condition that can markedly reduce the quality of life of affected individuals. Treatments taken by mouth (oral treatments), such as methotrexate, ciclosporin, and acitretin, are commonly prescribed to people with moderate to severe psoriasis. Oral fumaric acid esters (FAE) are licensed for the treatment of psoriasis in Germany but remain unlicensed in most other countries. This means that there are different treatment options offered to people in different countries.
cochrane.org
over 5 years ago